Comparative Pharmacology
Head-to-head clinical analysis: DIANEAL PD 1 W DEXTROSE 3 5 IN PLASTIC CONTAINER versus DIANEAL PD 2 W DEXTROSE 2 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIANEAL PD 1 W DEXTROSE 3 5 IN PLASTIC CONTAINER versus DIANEAL PD 2 W DEXTROSE 2 5 IN PLASTIC CONTAINER.
DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER vs DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dianeal PD-1 with dextrose 3.5% is a peritoneal dialysis solution that uses dextrose as an osmotic agent to create an osmotic gradient across the peritoneal membrane, facilitating the removal of waste products (urea, creatinine) and excess fluid from the blood into the dialysate.
Dianeal PD-2 with Dextrose 2.5% is a peritoneal dialysis solution that removes waste products and excess fluid from the blood via diffusion and ultrafiltration across the peritoneal membrane. Dextrose creates an osmotic gradient driving fluid removal; electrolytes (sodium, chloride, calcium, magnesium, lactate) correct electrolyte imbalances.
2-3 L intraperitoneally, dwell time 4-6 hours, 4-5 exchanges per day
Intraperitoneal administration: 2 to 2.5 liters per exchange, typically 4 exchanges per day, with dwell times of 4-6 hours during the day and 8-12 hours overnight. Concentration selected based on ultrafiltration needs.
None Documented
None Documented
Glucose: 1.5–2 hours (intraperitoneal administration leading to systemic absorption); clinical context: prolonged in renal impairment due to decreased clearance of metabolic products, but glucose itself is rapidly metabolized.
Not applicable; drug is not systemically absorbed. The peritoneal clearance of glucose follows first-order kinetics with a half-life of approximately 2-3 hours in the peritoneal cavity.
Renal (virtually 100% of absorbed dextrose and metabolites); peritoneal dialysis removes glucose and metabolic byproducts, but significant elimination occurs via transperitoneal absorption into systemic circulation followed by renal excretion (in patients with residual renal function). In anuric patients, glucose is metabolized and eliminated as CO2 and water, with minimal direct excretion.
Renal: negligible; drug is not absorbed systemically. The glucose is metabolized locally in peritoneal cavity and removed with dialysate outflow.
Category C
Category C
Peritoneal Dialysis Solution
Peritoneal Dialysis Solution